Ocular Therapeutix

Dr. Pravin U. Dugel is Executive Chairman, President, and CEO. He joined Ocular as Executive Chairman in 2023 and added the CEO role later that year. Dugel is a practicing retina specialist who previously served as managing partner of Retinal Consultants of Arizona and co-founder of several ophthalmic biotech firms, including Ophthotech (now IVERIC bio). His clinical practice and drug-development experience are central to Ocular's retina-focused pipeline strategy (per the firm's public filings, 2024).

DEXTENZA is a physician-administered, preservative-free dexamethasone insert placed in the lower punctum and canaliculus. It delivers a 0.4 mg tapered dose over approximately 30 days for post-operative ocular inflammation and pain following ophthalmic surgery. The plug resorbs and exits the nasolacrimal system naturally, requiring no patient compliance and no removal procedure. Medicare reimbursement became effective in 2019, and the product is covered under a transitional pass-through payment status that allows separate CMS payment in the ambulatory surgery center setting (per CMS, 2019).

OTX-TKI is an intravitreal hydrogel implant containing axitinib, a tyrosine kinase inhibitor that blocks VEGF receptors. In 2024, the firm initiated the SOL-R Phase 3 program, consisting of two independent pivotal trials designed to support a New Drug Application. A prior Phase 2 trial in Australia demonstrated durable treatment-free intervals exceeding 12 months in some subjects, which, if replicated, could meaningfully reduce the injection burden versus monthly anti-VEGF biologics. Topline Phase 3 data are expected in 2027 (per the firm's clinical trial registrations and investor communications, 2024).

Ocular raised approximately $325 million in a private placement of convertible senior notes in January 2024 from RA Capital Management, Avoro Capital Advisors, and Blue Owl Healthcare Opportunities, among others, extending its cash runway into 2028. Additional revenue comes from DEXTENZA and ReSure Sealant commercial sales, which are building through a direct specialty sales force targeting cataract and refractive surgeons (per the firm, January 2024).

No. Ocular Therapeutix is not an investment firm, family office, or venture capital vehicle. It is a publicly traded operating company that runs internal drug-development programs and a direct commercial sales force. All capital raised is deployed into clinical trials, manufacturing, and commercial infrastructure for its own pipeline. Institutional holders like RA Capital appear on the capitalization table, but the firm does not manage external capital or make fund commitments.

Ocular focuses exclusively on anterior segment and retinal disease treated via its intracanalicular or intravitreal delivery platforms. It does not pursue systemic therapies, oncology, dry-eye topical drops, or off-the-shelf generics. Within ophthalmology, the firm has explicitly deprioritized the OTX-CSI cyclosporine intracanalicular implant for dry eye disease; development was placed on hold in 2023 following Amgen's termination of a licensing partnership, redirecting resources to OTX-TKI and OTX-TIC (per the firm, 2023).

Most ophthalmic sustained-delivery systems — such as Allergan's Ozurdex or Roche's Susvimo — use intravitreal injections or surgically implanted refillable ports. Ocular's hydrogel punctal plug sits in the tear-drainage canaliculus, outside the vitreous cavity for anterior-segment drugs. For posterior-segment disease, OTX-TKI uses a bioresorbable intravitreal fiber, but the active agent is a small-molecule TKI rather than a biologic, offering potential advantages in durability and cost of goods. The common thread is resorbable hydrogel engineering that removes the need for repeat procedures or patient medication adherence (per the firm's SEC filings, 2024).